, with substantial environmental and, perhaps, epigenetic components. The polygenic and non-genetic components of major CNS diseases makes the use of genetically engineered mice to provide validated models for drug discovery efforts precarious 6 . Another fundamental difficulty with developing novel CNS therapeutics is the appreciation that the most widely prescribed CNS medications, especially those for mood disorders (for example, lithium, anticonvulsants and antidepressants 7 ) and schizophrenia 8 have complex and ill-defined mechanisms of action. As will be summarized below, the discovery that the most clinically effective CNS drugs are pharmacologically complex, with pleiotypic actions (that is, they act as 'magic shotguns'), has made the development of 'magic bullets' (that is, drugs selective for a single molecular target) less likely.
Why 'dirty' drugs might be better
Even though clozapine was discovered nearly 50 years ago 3 , it remains the 'gold standard' atypical antipsychotic drug because of the absence of debilitating extra-pyramidal sideeffects and demonstrated clinical superiority in treating schizophrenia 9 and in reducing suicidality 10 . However, clozapine is also associated with severe and potentially lifethreatening side effects, including an increased risk of agranulocytosis, seizures, weight gain and diabetes, and is therefore typically prescribed only for individuals with 'treatmentresistant' schizophrenia. Clozapine has a highly complex pharmacological profile, with high affinity for a number of serotonin (5-HT 2A , 5-HT 2C , 5-HT 6 , 5-HT 7 ), dopamine (D 4 ), muscarinic (M 1 , M 2 , M 3 , M 4 , M 5 ), adrenergic (α 1 -and α 2 -subtypes) and other biogenic amine receptors (REF. 8 and references cited therein). FIGURE 1 shows the distribution of some of the receptors targeted by clozapine in relation to various molecular targets implicated by genetic studies of schizophrenia (see REFS 4, 5 for details). As can be seen in FIG. 1 , many of the genes implicated in the aetiology of schizophrenia are found in anatomical loci where they could, directly or indirectly, modulate glutamatergic and dopaminergic neurotransmission in the frontal cortex. Clozapine is Most common central nervous system disorders -such as depression, bipolar disorder and schizophrenia -seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies. Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single molecular targets (that is, 'magic bullets') have, not surprisingly, been largely unsuccessful. Here we propose that designing selectively non-selective drugs (that is, 'magic shotguns') that interact with several molecular targets will lead to new and more effective medications for a variety of central nervous system disorders.
Despite their enormous potential to alleviate human suffering, before the introduction of fluoxetine (Prozac; Eli Lilly) in the late 1980s central nervous system (CNS) therapeutics were not widely embraced as either highly reliable or profitable. This is despite the fact that from the 1960s to the 1970s selected areas of CNS drug discovery yielded profitable drugs (for example, Valium, Milltown and Haldol). This was due, in part, to the lack of suitable animal models, disagreements regarding the biological basis of many disorders, uncertainty regarding the ultimate mechanism(s) of action and the clinical ineffectiveness of many CNS medications 1 . During the past two decades, CNS drug discovery -particularly in the areas of mood In addition to improving the core symptoms of schizophrenia, such as hallucinations and delusions, atypical antipsychotic drugs as a class modestly improve cognition 18 , though it is unknown how these cognition-enhancing actions are mediated. Current hypotheses suggest that the cognition-enhancing actions of atypicals may be due to interactions with 5-HT 2A 19 and 5-HT 6 20 receptors, and to their abilities to enhance prefrontal cortical dopamine release 21 (FIG. 1 . A graphical representation of the relative affinity values of clozapine and a number of other atypical antipsychotic drugs (aripiprazole, ziprasidone, zotepine, quetiapine, olanzapine, risperidone) and typical antipsychotic drugs (haloperidol, chlorpromazine) at a portion of the receptorome (that is, that portion of the proteome comprising receptors) is shown in FIG. 2. As can be seen, most of the presently approved atypical antipsychotic drugs have a complex pharmacology, with appreciable affinities for a variety of biogenic amine receptors. Given the huge potential market for atypical antipsychotic drugs (~US $10 billion annually), great effort has been devoted to uncovering the receptors responsible for effectiveness, for atypicality and for side effects. The idea has been that if one could design drugs that targeted the appropriate receptors, one could develop atypical antipsychotic drugs that are more effective than clozapine and have fewer side effects. These efforts will be furthered in the future by the precise delineation of the areas of the brain in which the drug exerts its beneficial effects, as well as characterization of the intracellular biochemical pathways contributing to both effectiveness and the development of side effects.
'S 2 /D 2 ' drugs: not quite clozapine
The first 'non-clozapine' atypical to be marketed was risperidone, which potently blocks the effects of lysergic acid diethylamide (LSD) in laboratory animals by virtue of its high affinity for 5-HT 2A receptors 11 . A systematic analysis of receptor pharmacology of a number of typical and atypical antipsychotic drugs led Meltzer 12 and others 13 to propose that the single distinguishing feature of an atypical antipsychotic drug was a relatively high affinity for 5-HT 2A relative to D 2 receptors (the 'S 2 /D 2 hypothesis of atypicality'). Subsequently, several atypical antipsychotic drugs were introduced that fulfilled the 'S 2 /D 2 ' criterion, including olanzapine, ziprasidone, zotepine and quetiapine. Although these drugs represent an advance in the treatment of schizophrenia, none of the presently approved atypical antipsychotic drugs is better than clozapine for schizophrenia 14, 15 . As a class, the 'S 2 /D 2 atypicals' are not without serious side effects, including weight gain and the associated metabolic sequelae of diabetes and hypercholesterolaemia 16 . In this regard, recent studies have implicated the histamine receptor H 1 , the 5-HT 2C receptor and α 1 -adrenoceptors -sites for which many atypical antipsychotic drugs have high affinity -for causing weight gain and associated metabolic side effects 17 . S 2 /D 2 atypicals that have relatively low affinity for H 1 receptor and α 1 -adrenoceptors (for example, ziprasidone) are less likely to induce weight gain. Because other CNS medications that induce weight gain, such as amitryptiline, mirtazepine and imipramine (see PDSP K i Database, Further Information), also have high H 1 , 5-HT 2C -and α 1 -adrenoceptor affinities, these data strongly imply that antipsychotic drugs that lack affinities at H 1 , 5-HT 2C and α 1 receptors will be less likely to induce the metabolic side effects of many of the presently marketed drugs. 33 . Likewise, the D 2 partial agonism has been inconsistently replicated, with some groups reporting that aripiprazole is a highaffinity partial agonist in vitro 34 , and others reporting that aripiprazole is a D 2 antagonist in vivo and in vitro 35 . By contrast, Lawler et al. 36 proposed that aripiprazole was 'functionally selective' and that the agonist properties of aripiprazole were entirely dependent on the cellular milieu in which it was studied. As a result, it was proposed 36 that aripiprazole might function as a D 2 antagonist, agonist or partial agonist depending on the precise complement of D 2 receptors and G-proteins in a particular cell. This notion is similar to the idea of agonist-directed trafficking of receptors (see REF. 37 for a recent review), an idea originally proposed many years ago 38 . This idea proposes that receptors can couple to several signal transducing molecules and suggests that "selective agonists and antagonists might be developed which have specific effects on a particular receptor-linked effector system." 38 When the various competing hypotheses of aripiprazole's actions were tested, we found 39 , in support of the hypothesis of Lawler et al. 36 , that the actions of aripiprazole were entirely dependent on the cellular milieu. Interestingly, we also discovered 39 that aripiprazole had a robust pharmacological profile with partial agonism at several 5-HT (5-HT 1A , 5-HT 2A , 5-HT 2C , 5-HT 7 ) and dopamine (D 2 , D 3 , D 4 ) receptors. So although aripiprazole is clearly a functionally selective partial agonist, its complex pharmacology precludes us from concluding that its beneficial actions in schizophrenia are due solely to partial agonism of D 2 receptors. It is more likely that the balance of partial agonism and antagonism at a multiplicity of receptors is responsible for its efficacy in schizophrenia and related disorders. Taken together, these findings have profound implications for CNS drug discovery, because they imply that simply developing selective low-efficacy D 2 partial agonists will not yield effective antipsychotic drugs, but that D 2 partial agonists that functionally interact with various 5-HT and dopamine receptors might be effective. Therefore functionally non-selective dopamine agonists might represent a new generation of atypical antipsychotic drugs, with aripiprazole being the first member of this class. schizophrenia, it was found to be effective for a short period (~one week), after which clinical efficacy was lost -presumably due to receptor desensitization 28 . Because (-)PPP has substantial affinities for non-D 2 receptors (for example, σ-, α 2B -or α 2C -adrenoceptors; see PDSP Database, Further Information), it is conceivable that the ineffectiveness of (-) PPP was due to unforeseen interaction with non-D 2 receptors. Intriguingly, (+)-UH232 actually worsened psychotic symptoms, perhaps via a combination of D 3 and 5-HT 2A agonism 29 , because 5-HT 2A agonism is known to exacerbate psychosis 62 . On the basis of these early trials, it was unclear whether (-)PPP's lack of efficacy beyond one week was due to either inadvertent interaction with psychotomimetic receptors (for example, σ 1 -adrenoceptor) or the relatively high intrinsic activity of (-)PPP leading to desensitization. Several other D 2 partial agonists, including terguride, OPC-4392, pramipexole and SDZ HDC 912, have now been tested in schizophrenia, mainly unsuccessfully 30 . To date, only aripiprazole (OPC 14597), a weak D 2 partial agonist 31 , has shown efficacy for schizophrenia 32 , although considerable controversy exists regarding its mechanism of action
Kikuchi et al. 31 originally proposed that aripiprazole was a presynaptic agonist and a treating schizophrenia. Likewise, the 5-HT 2A selective compound M100907 (REF. 24) failed to reduce symptoms to the same extent as haloperidol (a typical antipsychotic drug comparator) in a multi-centre clinical trial, whereas the 5-HT 2A/2C antagonist SR46349B fared better in comparison with haloperidol 25 (TABLE 1). There have also been suggestions that compounds with muscarinic 26 or adrenoceptors (both α 2 -and α 1 -adrenoceptors) actions might be effective antipsychotic drugs but, so far, none have shown efficacy in clinical trials (see REF. 8 and references cited therein). TABLE 1 lists a number of other 'magic bullets' which, with few exceptions, were shown to lack efficacy in schizophrenia.
Partial agonists for schizophrenia
Some years ago, Carlsson proposed that (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine ((-)PPP), by virtue of its autoreceptor agonist properties, might represent a prototype for a new family of atypical antipsychotic drugs 27 . Carlsson's notion was that a partial agonist would normalize or 'stabilize' dopaminergic neurotransmission in a way that would be salutary for both the positive and negative symptoms of schizophrenia. Two potential compounds were subsequently tested: (-)PPP and (+)-UH232 (a D 3 -preferring agonist with 5-HT 2A agonism). When (-)PPP was tested in that the large-scale, automated and random screening of libraries of compounds enriched for activity at CNS targets, using mainly behavioural assays, will yield compounds with novel and, possibly improved, efficacies for a variety of CNS diseases. These approaches carry with them the advantage of examining responses to drugs at the level of entire organisms, and therefore in the context of their biological functioning, rather than in overly simplified experimental systems, for example, as in isolated in vitro binding studies.
Another approach is a genomic one in which compounds are screened solely on the basis of their abilities to modify the
Non-selective antidepressants?
If 'dirty' drugs are better for treating schizophrenia than selective ('clean') ones, what about other CNS disorders? TABLE 2 lists the current classes of antidepressants, ranking them by their relative effectiveness in treating depression. The most effective treatment for depression -electroconvulsive therapy (ECT) -alters the dynamics of a vast number of neurotransmitters and neuromodulators, and has profound effects on intracellular signalling pathways related to signal transduction and mitogenesis 7 . Indeed, very recent studies imply that the pleiotypic actions of antidepressants on signal transduction and neuronal mitogenesis are required for the beneficial actions of antidepressants on mood 40 . Likewise, so-called 'dual-action' antidepressants, which inhibit the reuptake of both 5-HT and other biogenic amines (for example, dopamine and noradrenaline), have been shown to be more effective than 'single-action' antidepressants such as the SSRIs 41, 42 . As an added benefit, the 'dualaction' antidepressants also seem to effectively treat chronic pain 43 . Finally, recent genetic studies have implied that depression, like schizophrenia, is a complex disorder with linkage to several genes 44 , including many that converge on the transcription factor cAMP-responsive element binding protein-1 (CREB1). These results imply that improved treatments for mood disorders are likely to arise from drugs with several mechanisms of action, and that studies that connect new knowledge of genetic linkage of these diseases in humans with those of changes in gene regulation in disease, as well as after treatment, are likely to be helpful in the development of new therapies.
Implications for CNS drug discovery
Given that selectively non-selective drugs are likely to be more beneficial than singleaction agents in many CNS disorders, how best to develop them? Clearly, conventional approaches relying on high-throughput screening (HTS) of cloned human molecular targets and the subsequent optimization of these 'single-target agents' is not likely to yield selectively non-selective agents, except, perhaps, by chance. Structure-based drug design approaches in which ligands are designed to interact with the correct subset of molecular targets are also not likely to be successful. This is because many of the molecular targets selected have a high degree of structural similarity and designing drugs to target a subset of them is not likely to be successful (see REF. 63 for discussion).
The implication of these findings is that the screening of small molecules by nonconventional approaches should be considered.
Conceptually, at least two non-conventional approaches for discovering 'magic shotguns' can be envisioned: behaviour-based screening and genomic approaches. The first, which has been dubbed 'HTS'-based behavioural screening' 45, 46 , relies on the semi-automated screening of candidate drugs in broad-based behavioural assays. At least two novel antidepressants -YKP10A and INN 00835 -were discovered using this approach. Neither drug seems to have appreciable affinity for any known antidepressant drug target, including various biogenic amine receptors and transporters 47 , and both have demonstrated effectiveness in early-phase trials 48, 47 . It is probable NATURE REVIEWS | DRUG DISCOVERY VOLUME www.nature.com/reviews/drugdisc P E R S P E C T I V E S drugs -'magic shotguns' -could be discovered by combining behavioural and genomics-based screening. Once leads are discovered, potential toxicities could be relatively easily 'designed out' by counter-screening approaches combined with straight-forward medicinal chemistry approaches. Such magic shotguns, or selectively non-selective drugs, are likely to represent highly effective and novel treatments for major CNS disorders. The rational discovery, optimization and eventual marketing of selectively non-selective drugs will end our reliance on serendipity as the driving force for effective drug discovery for CNS disorders. On the other hand, in a gene K + channel for arrhythmias 50 and the 5-HT 2B receptor for fenfluramine-like valvular heart disease 51 ). In addition, it might prove possible to use combinations of compounds to 'fine-tune' these gene regulatory signatures.
The end of serendipity?
Historically, serendipity has been the driving force in the discovery of novel and highly effective drugs for CNS disorders. Not surprisingly, the most clinically effective treatments for depression and schizophrenia, and perhaps other disorders, continue to be the ones with the most nonspecific actions. It is likely that selectively non-selective coordinated expression of gene families. In this approach, compounds with known beneficial actions and pleiotypic actions (for example, lithium, clozapine) are screened in vivo and in vitro for their effects on coordinated gene expression. Once gene 'signatures' are discovered, compound libraries are subsequently screened to discover small molecules which, when administered in vitro and in vivo, yield similar signatures; such an approach is now being undertaken by Psychiatric Genomics, Inc. 49 . Lead compounds can then be optimized to eliminate interactions with potentially toxic molecular targets (for example, H 1 receptor for weight gain 17 , human ether-a-go-go-related 
